Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Shareholders' Equity (Parenthetical)

v2.4.0.6
Consolidated Statements of Shareholders' Equity (Parenthetical) (USD $)
12 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Pharmacos Exakta
Dec. 31, 2011
Fine Tech
Dec. 31, 2012
OURLab
Dec. 31, 2011
OPKO Diagnostics acquisition
Dec. 31, 2012
Farmadiet acquisition
Dec. 31, 2011
Common Stock
Dec. 31, 2010
Common Stock
Pharmacos Exakta
Dec. 31, 2011
Common Stock
Fine Tech
Dec. 31, 2012
Common Stock
OURLab
Dec. 31, 2011
Common Stock
OPKO Diagnostics acquisition
Dec. 31, 2011
Treasury
Dec. 31, 2011
Treasury
OPKO Diagnostics acquisition
Dec. 31, 2012
Treasury
Farmadiet acquisition
Dec. 31, 2011
Additional Paid-In Capital
Dec. 31, 2010
Additional Paid-In Capital
Pharmacos Exakta
Dec. 31, 2011
Additional Paid-In Capital
Fine Tech
Dec. 31, 2012
Additional Paid-In Capital
OURLab
Dec. 31, 2011
Additional Paid-In Capital
OPKO Diagnostics acquisition
Dec. 31, 2012
Additional Paid-In Capital
Farmadiet acquisition
Issuance of Common Stock, per share $ 3.75           $ 3.75               $ 3.75          
Repurchase of Common Stock, per share $ 3.27                     $ 3.27                
Issuance of Common Stock for acquisition   $ 1.46 $ 4.90 $ 4.65 $ 5.04 $ 4.12   $ 1.46 $ 4.90 $ 4.65 $ 5.04   $ 5.04 $ 4.12   $ 1.46 $ 4.90 $ 4.65 $ 5.04 $ 4.12